Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma

J. Clark,Benjamin Kelley,Jill Titze,Henry C. Fung,John Maciejewski,Sunita Nathan,Elizabeth Rich,Sanjib Basu,Howard L. Kaufman

Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma

2013

J. Clark
Benjamin Kelley
Jill Titze
Henry C. Fung
John Maciejewski
Sunita Nathan
Elizabeth Rich
Sanjib Basu
Howard L. Kaufman

Objective: High-dose interleukin-2 (IL-2) is effective immunotherapy for the treatment of metastatic melanoma and renal cell carcinoma (RCC) but has been contrain

Keywords:

Pathology
Melanoma
Interleukin 2
Immunotherapy
Medicine
Renal cell carcinoma
Survival rate
Contraindication
Dosing
Adverse effect
Prospective cohort study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations